{"filing":{"accession_number":"0001193125-26-324917","cik":"0001631574","ticker":"WVE","company_name":"Wave Life Sciences Ltd.","form":"8-K","filing_date":"2026-07-30","report_date":"2026-07-30","primary_document":"d177737d8k.htm","primary_document_url":"https://www.sec.gov/Archives/edgar/data/1631574/000119312526324917/d177737d8k.htm"},"events":[{"id":22090,"run_id":19960,"accession_number":"0001193125-26-324917","anchor_item_number":"2.02","event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.94,"summary":"Wave Life Sciences announced Q2 2026 financial results via press release, disclosing quarterly revenue of $2.3 million, R\u0026D expenses of $51.3 million, net loss of $69.4 million, cash position of $490.6 million with runway guidance into 3Q 2028, and clinical pipeline updates.","company_name":"Wave Life Sciences Ltd.","ticker":"WVE","filing_date":"2026-07-30","form":"8-K","submitted_at":null,"items":[{"id":21926,"accession_number":"0001193125-26-324917","item_number":"2.02","item_title":null,"event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Wave Life Sciences announced its financial results for the quarter ended June 30, 2026 via press release furnished as Exhibit 99.1. The disclosure includes quarterly financial metrics (revenue of $2.3 million, R\u0026D expenses of $51.3 million, net loss of $69.4 million), cash position ($490.6 million), and cash runway guidance into 3Q 2028, along with pipeline and business updates. This is a standard earnings release disclosure under Item 2.02.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-30T11:39:41.133101+00:00","company_name":"","ticker":null,"filing_date":""},{"id":21927,"accession_number":"0001193125-26-324917","item_number":"7.01","item_title":null,"event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"Item 7.01 furnishes an updated corporate presentation, but the substantive disclosure is the earnings release (EX-99.1) announcing Q2 2026 financial results and business updates. The filing explicitly references \"Items 2.02 and 7.01\" together, and EX-99.1 contains the full earnings announcement with quarterly financial results (revenue of $2.3M, net loss of $69.4M), cash position ($490.6M), and clinical pipeline milestones. This is a material earnings disclosure for a clinical-stage biotech company.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-30T11:39:41.133101+00:00","company_name":"","ticker":null,"filing_date":""}]}],"classifications":[{"id":21926,"accession_number":"0001193125-26-324917","item_number":"2.02","item_title":null,"event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.95,"reasoning":"Wave Life Sciences announced its financial results for the quarter ended June 30, 2026 via press release furnished as Exhibit 99.1. The disclosure includes quarterly financial metrics (revenue of $2.3 million, R\u0026D expenses of $51.3 million, net loss of $69.4 million), cash position ($490.6 million), and cash runway guidance into 3Q 2028, along with pipeline and business updates. This is a standard earnings release disclosure under Item 2.02.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-30T11:39:41.133101+00:00","company_name":"Wave Life Sciences Ltd.","ticker":"WVE","filing_date":"2026-07-30"},{"id":21927,"accession_number":"0001193125-26-324917","item_number":"7.01","item_title":null,"event_type":"earnings_release","event_domain":"financial","is_material":true,"confidence":0.92,"reasoning":"Item 7.01 furnishes an updated corporate presentation, but the substantive disclosure is the earnings release (EX-99.1) announcing Q2 2026 financial results and business updates. The filing explicitly references \"Items 2.02 and 7.01\" together, and EX-99.1 contains the full earnings announcement with quarterly financial results (revenue of $2.3M, net loss of $69.4M), cash position ($490.6M), and clinical pipeline milestones. This is a material earnings disclosure for a clinical-stage biotech company.","classifier_version":"claude-haiku-4-5-20251001+prompt-a85dd512","taxonomy_version":"v1.3","classified_at":"2026-07-30T11:39:41.133101+00:00","company_name":"Wave Life Sciences Ltd.","ticker":"WVE","filing_date":"2026-07-30"}]}